July-December North American Biologics Manufacturing Capital Projects, an Industrial Info Market Brief
July-December North American Biologics Manufacturing Capital Projects, an Industrial Info Market Brief
Attachment: biologics
Starting with insulin three decades ago, biologics have become the fastest-growing class of therapeutic compounds. Sales of biologics are expected to exceed $275 billion annually by 2019. About 300 biologics, which are costly to produce, are now available for human use. These compounds are widely accepted as the most effective means of treating certain diseases, including cancer and rheumatoid arthritis. Industrial Info's Pharmaceutical-Biotech Industry Market Platform is tracking 43 North American biologics manufacturing capital projects worth $2.06 billion that are set for kickoff in the last half of 2018.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- México registra inversiones por 2 mil millones de dólares en el sector farm...
- Mexico Registers US$2 Billion in Pharmaceutical Investments
- New England Sees $27 Billion in Projects Under Construction
- Pharma, Manufacturing Lead Indiana to $21.6 Billion of Projects Under Const...
- India Aims to Reduce Dependence on China for Pharma Market